- Home
- ACHR vs LEGN Comparison
ACHR vs LEGN Comparison
Compare ACHR & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACHR | LEGN |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | United States |
| Employees | 1148 | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 5.9B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ACHR | LEGN |
|---|---|---|
| Price | $6.04 | $17.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | $12.00 | ★ $63.08 |
| AVG Volume (30 Days) | ★ 25.5M | 1.5M |
| Earning Date | 03-02-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12,475.67 | $46.27 |
| Revenue Next Year | $900.00 | $28.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.48 | $16.24 |
| 52 Week High | $14.62 | $45.30 |
Technical Indicators
Market Signals| Indicator | ACHR | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 38.25 | 42.22 |
| Support Level | N/A | $17.46 |
| Resistance Level | $7.55 | $20.39 |
| Average True Range (ATR) | 0.38 | 0.73 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 15.52 | 12.80 |
Price Performance
Historical ComparisonAbout ACHR Archer Aviation Inc.
Archer Aviation Inc advances the benefits of sustainable air mobility. The company is engaged in designing and developing a fully electric vertical takeoff and landing eVTOL aircraft for use in UAM networks. It is creating an electric airline that moves people throughout cities in a quick, safe, sustainable, and cost-effective manner. The company is building a platform to deliver aircraft, technologies, and services to customers world-wide across commercial and defense sectors.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.